RxDoctor Payments DataLook up a doctor →

Randy Gelow, MD

Family Medicine · Phoenix, AZNPI 1568755130

Payments from drug & device makers

$68,662in general payments, 2019–2025

Across 548 payments — averaging $125.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Viiv Healthcare Company$61K
  • Gilead$4K
  • Merck$848
  • Braeburn Inc.$372
  • Napo Pharmaceuticals Inc$367
  • Novo Nordisk$348
  • plus $2K from 23 others

What the payments were for

  • Speaking & faculty fees$35,42563%
  • Travel & lodging$6,05111%
  • Food & beverage$14,08625%
  • Education$4481%
  • Gifts$1760%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$68,662 in reported general payments places this provider in the 95th percentile of 2,099 family medicine providers in Arizona.

See all family medicine providers in Arizona

Medicare billing

Part B allowed, 2024
$50,735
Medicare patients
110
Services billed
603

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala272$1,149,712
DescovyEmtricitabine/Tenofov Alafenam76$192,189
DovatoDolutegravir Sodium/Lamivudine43$133,983
PrezcobixDarunavir/Cobicistat39$117,120
TivicayDolutegravir Sodium40$87,688
OdefseyEmtricitab/Rilpiviri/Tenof Ala18$71,127
TriumeqAbacavir/Dolutegravir/Lamivudi13$56,440
DelstrigoDoravirine/Lamivu/Tenofov Diso13$36,871
Wellbutrin XlBupropion Hcl11$29,078
MounjaroTirzepatide26$27,607
TrulicityDulaglutide23$23,296
JardianceEmpagliflozin20$20,341
EliquisApixaban12$20,329
PifeltroDoravirine12$19,881
EdurantRilpivirine Hcl11$18,556

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadBiktarvy, Descovy$3,818$1,341,901348 claims
Viiv Healthcare CompanyDovato, Tivicay, Triumeq$61,283$278,11196 claims
Johnson & JohnsonPrezcobix$70$117,12039 claims
MerckDelstrigo, Pifeltro, Janumet Xr$848$69,41341 claims
Lilly USA, LLCMounjaro, Trulicity$17$50,90449 claims
Boehringer IngelheimJardiance$68$20,34120 claims
PfizerEliquis$15$20,32912 claims
Janssen Scientific Affairs, LLCEdurant$240$18,55611 claims
AstraZenecaSymbicort$73$3,62011 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,099 family medicine providers in Arizona.

Other family medicine in Phoenix

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →